Genomeditech (Shanghai) Co.,Ltd.
Order: 021-68455258/50432826/50432825
Toll-free: 400 627 9288
Email: service@genomeditech.com

Anti-TrkB hIgG4 Antibody (H4H9816P2)

Product information

GM-88117AB-10	10 μg
GM-88117AB-100	100 μg
GM-88117AB-1000	1 mg

Antibody Information

Species Reactivity	Human;
Clone	H4H9816P2
Source/Isotype	Human IgG4(S228P/H434R/Y435F/L445P) ,Kappa
Application	/
Specificity	Detects TrkB
Gene	TrkB
Other Names	NTRK2,TRKB,GP145-TrkB
Gene ID	4915 (human)
Background	TrkB gene (NTRK2) encodes tyrosine kinase receptor B, which belongs to the neurotrophin receptor family and plays a key role in the development, differentiation, survival and synaptic plasticity of the nervous system. Its natural ligand brain-derived neurotrophic factor (BDNF) regulates neuronal growth, differentiation and survival by activating TrkB and triggering downstream signaling pathways such as PI3K/AKT, RAS/MAPK and PLC γ. However, the aberrant activation of TrkB is closely related to the occurrence and progression of multiple malignancies, especially in solid tumors such as neuroblastoma, endometrial cancer, ovarian cancer, non-small-cell lung carcinoma, etc. , trkB is constantly activated by gene fusion, overexpression or mutation, which drives tumor cell proliferation, invasion, metastasis and anti-apoptosis. In addition, NTRK gene fusions, such as those of NTRK2 with other genes, result in sustained activation of TrkB, which drives tumor growth without ligand, becoming a driver in multiple cancers. Based on these findings, targeted therapeutic strategies against TrkB, such as TRK inhibitors (larotinib, emtrotinib, etc.) , have demonstrated therapeutic potential across cancer species, and the potential of targeting TrkB for cancer therapy has been well established, providing new therapeutic options for patients with NTRK fusion-positive tumors.
Storage	Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.

Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay

SDS-PAGE



On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is more than 95% verified by SEC-HPLC.